Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborator:
Alkermes, Inc.
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00325364
First received: May 10, 2006
Last updated: November 21, 2016
Last verified: November 2016